BDX Price sensitive 19 Nov 2026, 2:39 PM

BCAL Position on GSS-MAP Merger

Bcal Diagnostics Ltd

BCAL's Position on GSS-MAP Merger

Key points

  • BCAL prepared to support GSS-MAP merger on appropriate terms
  • BCAL considers funding MAP for working capital
  • Support conditional on GSS Board restructure
  • BCAL largest shareholder of GSS

Full summary

BCAL Diagnostics Limited (ASX: BDX) (BCAL), as the largest shareholder of Genetic Signatures Limited (ASX: GSS) (GSS), has noted the merger announcement between GSS and Microba Life Sciences Limited (ASX: MAP) (MAP) on 18 November 2026. BCAL is prepared to support the merger under specific conditions, including a revised term sheet and scheme implementation deed. BCAL would also consider providing funding to MAP of up to $2 million, subject to its own capital raising. BCAL's support is conditional on the restructure of the GSS Board, including the resignation of the GSS Chair.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in